-
1 week ago | 
neurologyadvisor.com | Hibah Khaja
Coenzyme Q10 (CoQ10) supplementation is significantly associated with headache resolution in pediatric patients diagnosed with new daily persistent headache (NDPH), according to study results presented at the 2025 American Headache Society (AHS) Annual Scientific Meeting, held from June 19-22, in Minneapolis, Minnesota, and virtually.
-
1 week ago | 
rheumatologyadvisor.com | Hibah Khaja
Among patients with metastatic nonsmall cell lung cancer (mNSCLC) receiving immune checkpoint inhibitors, those with vs without coexisting rheumatoid arthritis (RA) experience similar overall survival outcomes, according to study results published in ACR Open Rheumatology. These findings suggest that RA, despite its autoimmune nature and associated immunosuppressive treatments, should not be considered a contraindication to ICI therapy among patients with advanced lung cancer.
-
1 week ago | 
rheumatologyadvisor.com | Hibah Khaja
Sudden cardiac death and multiorgan pathology may be more closely linked to systemic sclerosis (SSc) than previously recognized, with myocardial fibrosis occurring independently of traditional causes in the majority of cases, according to study findings published in Seminars in Arthritis & Rheumatism.
-
1 week ago | 
neurologyadvisor.com | Hibah Khaja
In adult patients with migraine and comorbid major depressive disorder (MDD), treatment with fremanezumab is associated with significant reductions in both monthly migraine days (MMDs) and depressive symptoms, according to study results published in JAMA Neurology.
-
2 weeks ago | 
rheumatologyadvisor.com | Hibah Khaja
Approximately 116,000 to 118,000 adults in the United States may be living with interstitial lung disease (ILD) associated with connective tissue diseases (CTD), with the highest incidence and prevalence rates observed among older individuals and women, according to study results presented at the European Alliance of Associations for Rheumatology (EULAR) Congress 2025, held from June 11 to 14 in Barcelona, Spain.
-
2 weeks ago | 
neurologyadvisor.com | Hibah Khaja
In patients with Parkinson disease (PD) and comorbid mood dysfunction, psilocybin-assisted therapy is well-tolerated and associated with sustained improvements in depression, anxiety, motor symptoms, and cognitive flexibility. These are the results of a study published in Neuropsychopharmacology. Mood dysfunction, including depression and anxiety, are common nonmotor symptoms of PD due to the accumulation of α-synuclein.
-
2 weeks ago | 
rheumatologyadvisor.com | Hibah Khaja
The use of rituximab (RTX) significantly diminishes the humoral immune response to the recombinant herpes zoster vaccine (RZV) among patients with autoimmune rheumatic diseases (ARDs), according to study results presented at the European Alliance of Associations for Rheumatology (EULAR) Congress 2025, held from June 11 to 14 in Barcelona, Spain. Rituximab, a B cell-depleting therapy commonly used to treat ARDs, has been associated with increased infection risk.
-
2 weeks ago | 
endocrinologyadvisor.com | Hibah Khaja
Transgender and gender-questioning adolescents experience significantly higher rates of adverse childhood experiences (ACEs) compared with cisgender peers, according to a research letter published in JAMA Pediatrics. Although disparities in ACE exposure among adolescents based on sex and sexual orientation have been previously documented, few studies have systematically evaluated differences based on gender identity.
-
2 weeks ago | 
rheumatologyadvisor.com | Hibah Khaja
Treatment with bimekizumab (BKZ), a monoclonal antibody targeting interleukin (IL)-17A and IL-17F, led to sustained improvements in joint and skin outcomes over 3-years among biologic-naïve patients with active psoriatic arthritis (PsA), according to study results presented at the European Alliance of Associations for Rheumatology (EULAR) Congress 2025, held from June 11 to 14 in Barcelona, Spain.
-
2 weeks ago | 
rheumatologyadvisor.com | Hibah Khaja
Treatment with open-label tofacitinib leads to rapid and sustained improvements in disease activity among children and adolescents with active systemic juvenile idiopathic arthritis (sJIA), according to study results presented at the European Alliance of Associations for Rheumatology (EULAR) Congress 2025, held from June 11 to 14 in Barcelona, Spain. However, results from the randomized withdrawal phase of the trial did not significantly prolong time to flare compared with placebo.
